MIV Therapeutics Reports Scientific and Business Achievements in Corporate Review for First Six Months of 2005; Milestones Position Company as Leading Innovator of Next-Generation Biocompatible Coronary Stents and Drug-Delivery Technologies.
Permanent Link:
http://vlex.com/vid/miv-achievements-biocompatible-coronary-stents-55619314
Id. vLex: VLEX-55619314
Acceda a este documento
y pruebe vLex GRATIS durante 3 días
MIV Therapeutics Reports Scientific and Business Achievements in Corporate Review for First Six Months of 2005; Milestones Position Company as Leading Innovator of Next-Generation Biocompatible Coronary Stents and Drug-Delivery Technologies.
VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies for the treatment of cardiovascular disease, has reported significant progress in a report outlining the achievement of numerous key corporate and technological objectives for the first half of 2005. MIVT has systematically reinforced its strategic goal to capitalize on proprietary Hydroxyapatite (HAp) coating technologies, which have demonstrated consistently high levels of safety and biocompatibility in repeated scientific studies.
The Company's achievements for the first ...Try vLex for FREE for 3 days
Access legal information from United States including:
- Constitutions
- Forms and Contracts
- Legal Books and Journals
- Case Law
- News and Business
- Regulations
- U.S. Code
Try vLex without any commitment for 3 days and see why you need it.
3
days of Free Access
If you are already a vLex customer, Access Here
